Attention Deficit Hyperactivity Disorder Study
ID Number 09-1825Principal Investigator(s)
Department(s) or Division(s)
The purpose of this study is to examine the response to a commonly prescribed medication that is FDA approved for treatment of ADHD in children and adolescents. The study will include weekly visits with study physicians, evaluations for ADHD and other disorders, and medication for the treatment of ADHD. Jeffrey Newcorn, M.D., the principal investigator of the study, is the Director of the Division of Child & Adolescent Psychiatry at Mount Sinai School of Medicine.
GCO# 09-1825(0001) IRB approved through 11/2/14
Beth K. Krone, CRC
Recruiting Patients: Yes